AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Betashares Space Industry ETF

9.760

-0.300-2.98%

Volume:45.15K

Turnover:445.04K

Market Cap:40.99M

PE:- -

High:10.100

Open:10.000

Low:9.750

Close:10.060

52wk High:19.000

52wk Low:8.710

Shares:4.20M

Float Shares:4.20M

Volume Ratio:1.61

T/O Rate:1.08%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Rocket Pharmaceuticals' Danon, PKP2-ACM Updates Seen as Key H2 Catalysts, Wedbush Says

MT Newswires Live

Wedbush Adjusts PT on Rocket Pharmaceuticals to $15 From $16, Keeps Outperform Rating

MT Newswires Live

Units on Issue Disclosure - July 2026

Units on Issue Disclosure - June 2026

Product Disclosure Statement

Units on Issue Disclosure - May 2026

Admission and Commencement of Trading - RCKT-RCK

Rocket Pharmaceuticals' Cardiac Programs Updates to Offer 'Strong' Share Price Catalysts, Wedbush Says

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/RCKT.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RCKT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RCKT.AU\",,,,,undefined,":{"symbol":"RCKT.AU","market":"AU","secType":"STK","nameCN":"Betashares Space Industry ETF","latestPrice":9.76,"timestamp":1787292720000,"preClose":10.06,"halted":0,"volume":45151,"delay":0,"changeRate":-0.02982107355864818,"nameEN":"Betashares Space Industry ETF","floatShares":4200000,"shares":4200000,"eps":0,"marketStatus":"Market Closed","change":-0.3,"latestTime":"08-21 16:12:00 AEST","open":10,"high":10.1,"low":9.75,"amount":445041,"amplitude":0.034791,"askPrice":10.98,"askSize":272,"bidPrice":9.75,"bidSize":109,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":10.06,"nav":9.775151,"aum":41544391,"bidAskSpread":0,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":1.6070487974218686,"lotSize":0,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RCKT.AU","preClose":10.06,"auctionPrice":10,"auctionVolume":1120,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292249990}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RCKT.AU\",,,,,undefined,":{"symbol":"RCKT.AU","floatShares":4200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.6070487974218686,"shares":4200000,"dividePrice":0,"high":10.1,"amplitude":0.034791,"preClose":10.06,"low":9.75,"week52Low":8.71,"pbRate":"--","week52High":19,"institutionHeld":0,"latestPrice":9.76,"committee":-0.427822,"eps":0,"divideRate":0,"volume":45151,"delay":0,"ttmEps":0,"open":10,"prevYearClose":14,"prevWeekClose":10.72,"prevMonthClose":9.12,"prevQuarterClose":12.13,"fiveDayClose":10.72,"twentyDayClose":9.56,"sixtyDayClose":17.71},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RCKT.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RCKT.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RCKT.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658122609","title":"Rocket Pharmaceuticals' Danon, PKP2-ACM Updates Seen as Key H2 Catalysts, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2658122609","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658122609?lang=en_us&edition=fundamental","pubTime":"2026-08-12 01:36","pubTimestamp":1786469782,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals' (RCKT) Q2 update confirmed its programs are on track, with management expecting regulatory updates on RP-A501 for Danon disease and RP-A601 for PKP2-ACM in H2, Wedbush Securiti","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0689626769.HKD","LU2244417387.USD","LU0124676726.USD","LU2360107325.USD","ACM","RCKT","BK4139","LU2298064838.USD","LU2308191902.HKD","LU1939255532.USD","LU1861214812.USD","LU1861219969.SGD","LU2238339852.HKD","BK4516","BK4129","LU0187121727.USD","RCKT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658299010","title":"Wedbush Adjusts PT on Rocket Pharmaceuticals to $15 From $16, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2658299010","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658299010?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:15","pubTimestamp":1786450548,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals (RCKT) has an average rating of overweight and mean price target of $8.84, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RCKT.AU","BK4139","RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657686613","title":"Units on Issue Disclosure - July 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657686613","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657686613?lang=en_us&edition=fundamental","pubTime":"2026-08-06 16:21","pubTimestamp":1786004479,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260806:nASX8s6Gmw","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nASX8rMld1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLD.AU","HETH.AU","YMAX.AU","OOO.AU","CLDD.AU","ASIA.AU","WRLD.AU","UTIP.AU","ARMR.AU","GBND.AU","RCKT.AU","YANK.AU","CRED.AU","FOOD.AU","BGBL.AU","AUDS.AU","HVST.AU","ATEC.AU","30BB.AU","WBND.AU","COMP.AU","QMAX.AU","URNM.AU","A200.AU","28BB.AU","BHYB.AU","FUEL.AU","DBBF.AU","SMLL.AU","BBFD.AU","EXUS.AU","DZZF.AU","DGGF.AU","MTUM.AU","HQLT.AU","QLTY.AU","AAA.AU","QNDQ.AU","BNDS.AU","QUS.AU","JNDQ.AU","AGVT.AU","ETHI.AU","IIND.AU","QBTC.AU","ROYL.AU","FAIR.AU","HQUS.AU","GGAB.AU","EX20.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649264651","title":"Units on Issue Disclosure - June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2649264651","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649264651?lang=en_us&edition=fundamental","pubTime":"2026-07-06 14:11","pubTimestamp":1783318272,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260706:nASX8TXXTm","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nASX96PLwx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QFN.AU","BBAB.AU","CFLO.AU","ASIA.AU","ETHI.AU","XMET.AU","UMAX.AU","BNDS.AU","BHYB.AU","HACK.AU","HYLD.AU","GGOV.AU","DBBF.AU","QPON.AU","RCKT.AU","EXUS.AU","URNM.AU","31BB.AU","HQUS.AU","RBTZ.AU","YANK.AU","BGBL.AU","A200.AU","GBND.AU","HJPN.AU","CLDD.AU","QLTY.AU","GGAB.AU","JNDQ.AU","BEMG.AU","USD.AU","FOOD.AU","GAME.AU","F100.AU","CRED.AU","QUS.AU","EX20.AU","FAIR.AU","QRE.AU","MMKT.AU","HBRD.AU","AUDS.AU","ROYL.AU","QOZ.AU","AEBD.AU","AAA.AU","DHHF.AU","GGFD.AU","BBOZ.AU","US10.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641211872","title":"Product Disclosure Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2641211872","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641211872?lang=en_us&edition=fundamental","pubTime":"2026-06-05 15:14","pubTimestamp":1780643640,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260605:nASX4DpvQ6","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nASXbLHRhg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLTY.AU","RBTZ.AU","ASIA.AU","INCM.AU","RCKT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640131632","title":"Units on Issue Disclosure - May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640131632","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640131632?lang=en_us&edition=fundamental","pubTime":"2026-06-04 12:06","pubTimestamp":1780545985,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260604:nASX8DPW3y","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nASXbXWdtV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEBD.AU","QNDQ.AU","BGBL.AU","QBTC.AU","DBBF.AU","HNDQ.AU","RCKT.AU","US10.AU","ASIA.AU","28BB.AU","IIND.AU","HQUS.AU","ROYL.AU","QLTY.AU","ATEC.AU","HEUR.AU","OOO.AU","BBAB.AU","AQLT.AU","DRUG.AU","BNDS.AU","HBRD.AU","YANK.AU","MTUM.AU","INCM.AU","BNKS.AU","MNRS.AU","EX20.AU","QETH.AU","30BB.AU","QAU.AU","OZBD.AU","HETH.AU","BBOZ.AU","HGBL.AU","HQLT.AU","USD.AU","GGOV.AU","CFLO.AU","QOZ.AU","AUST.AU","FUEL.AU","BEMG.AU","GTUM.AU","A200.AU","ARMR.AU","H100.AU","GGAB.AU","DRIV.AU","F100.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634422455","title":"Admission and Commencement of Trading - RCKT-RCK","url":"https://stock-news.laohu8.com/highlight/detail?id=2634422455","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634422455?lang=en_us&edition=fundamental","pubTime":"2026-05-11 07:42","pubTimestamp":1778456574,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260510:nASX5cRHQv","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260510:nASX17xh3s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCKT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634632214","title":"Rocket Pharmaceuticals' Cardiac Programs Updates to Offer 'Strong' Share Price Catalysts, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2634632214","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634632214?lang=en_us&edition=fundamental","pubTime":"2026-05-09 00:18","pubTimestamp":1778257134,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals'  clinical and regulatory updates on its three cardiac gene therapy programs in H2 are expected to serve as \"strong\" share price catalysts, Wedbush Securities said in a note Friday.All three programs are advancing as planned, with management expected to provide an update on RP-A501 for Danon disease once alignment is reached with the US Food and Drug Administration, which should bring the program back on track, the brokerage said. A discussion of disease prevalence is critical amid questions on the size of the market opportunity, Wedbush added.For RP-A601 targeting PKP2-related arrhythmogenic cardiomyopathy, Rocket is in talks with the FDA for the final design of a potential pivotal phase 2 study, while the phase 1 study remains open due to patients' demand to undergo treatment without waiting for the next study, the brokerage said.Rocket's RP-A701 program for BAG3-associated dilated cardiomyopathy is also on track to begin a phase 1 study with a fast track desig","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RCKT.AU","RCKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}]}}